Trial reportEuropean journal of haematology2026
Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY-1 and MOMENTUM Trials.
Trial report in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
A Randomized, Double-blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic, Anemic Subjects With Primary Myelofibrosis (PMF), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Who Were Previously Treated With JAK Inhibitor Therapy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesThese post hoc analyses of 2 phase 3 myelofibrosis trials assessed the kinetics and prognostic value of achieving hemoglobin ≥ 10 g/dL with momelotinib.
methodsMedian (range) time to hemoglobin ≥ 10 g/dL was assessed in momelotinib-randomized patients with baseline hemoglobin < 10 g/dL in the SIMPLIFY-1 (JAK inhibitor naive) and MOMENTUM (JAK inhibitor experienced) trials. Survival from treatment initiation was evaluated via Kaplan-Meier curves and Cox models.
resultsIn SIMPLIFY-1, 54/86 patients (63%) achieved hemoglobin ≥ 10 g/dL by week 24: moderate anemia, 40/58 (69%), 0.6 (0.4-5.1) months; severe anemia, 14/28 (50%), 1.4 (0.5-4.7) months. In MOMENTUM, 45/126 patients (36%) achieved hemoglobin ≥ 10 g/dL by week 24: moderate anemia, 30/64 (47%), 0.5 (0.3-4.6) months; severe anemia, 15/62 (24%), 0.5 (0.5-5.6) months. Achieving hemoglobin ≥ 10 g/dL by week 24 was numerically associated with longer survival: SIMPLIFY-1 HR, 0.53 (95% CI, 0.27-1.05); MOMENTUM HR, 0.62 (95% CI, 0.33-1.15). In multivariate analysis, only week 24 transfusion independence was associated with survival.
conclusionsAchievement of hemoglobin ≥ 10 g/dL may be a clinically meaningful target in momelotinib-treated patients with myelofibrosis and anemia. Those without JAK inhibitor experience and/or with moderate anemia were more likely and faster to achieve this threshold, supporting earlier momelotinib initiation to optimize outcomes.
trial registrationCLINICALTRIALS. GOV IDENTIFIER: NCT01969838, NCT04173494.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.